Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding. Ciccullo A, Borghi V, Giacomelli A, Cossu MV, et al. J Acquir Immune Defic Syndr 2021 Aug 20. pii: 00126334-900000000-95820.

Read + Share

Amedeo Smart

Independent Medical Education

Ciccullo A, Borghi V, Giacomelli A, Cossu MV, et al. Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding. J Acquir Immune Defic Syndr 2021 Aug 20. pii: 00126334-900000000-95820.
PMID: 34446677